Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B

Joseph Larmarange, Valentine Becquet, Jean-Marie Masumbuko, Marcellin Nouaman, Mélanie Plazy, Christine Danel, Serge Eholié

To cite this version:

Joseph Larmarange, Valentine Becquet, Jean-Marie Masumbuko, Marcellin Nouaman, Mélanie Plazy, et al.. Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B. AIDS, Lippincott, Williams & Wilkins, 2018, 32 (6), pp.829-830. 10.1097/QAD.0000000000001749 . hal-02360409

HAL Id: hal-02360409
https://hal.archives-ouvertes.fr/hal-02360409
Submitted on 12 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B

When taken properly, Tenofovir-based oral preexposure prophylaxis (PrEP) has been proven to be efficient to prevent HIV acquisition [1–5]. Since 2015, PrEP is recommended by the WHO for populations at ‘substantial risk’ of HIV [6]. However, WHO points out the need for additional research on PrEP in ‘real life’ on questions such as demand creation for oral PrEP; best delivery models in different contexts and for different populations; social and behavioral impact of PrEP; or integration of PrEP services with other services [6]. Transitioning from efficacy trials to implementation requires to adapt interventions. Preliminary research (ANRS 12361 PrEP-CI [7]) has been conducted in Côte d’Ivoire (CI) in collaboration with community non-governmental organizations to explore relevance and feasibility of implementing a PrEP program among female sex workers, one of the most exposed populations countrywide (estimated HIV prevalence: 29% [8]). The following observations emerged from that collective work.

All efficacy PrEP trials provided a range of sexual healthcare services in addition to PrEP drugs [9–11]. Such services appeared essential for any PrEP program. By design, they were conditional to PrEP use. However, regardless of their interest in using PrEP, female sex workers interviewed in Côte d’Ivoire, and more broadly key populations worldwide [12–16], have many unmet sexual and reproductive health needs: sexually transmitted infections screening and care, contraception and birth control, menstrual management, addictions and risky behaviors… When transitioning to real life, we should not reproduce the service model of efficacy PrEP trials, that is a PrEP program with additional services. Instead, a paradigm shift toward a patient-centered approach should be preferred, that is offering sexual and reproductive health services in which PrEP is an option but not mandatory.

In Western and Central Africa, the prevalence of hepatitis B is relatively high [17]. In Côte d’Ivoire, more than 11% of new blood donors were positive for hepatitis B surface antigen in 2008–2012 [18]. Tenofovir is also used for hepatitis B treatment. But, currently, treatment is not free for monoinfected hepatitis B patients, whereas it is covered by AIDS programs for HIV-hepatitis B coinfected patients. In such context, it would be ethically unacceptable to provide free HIV PrEP without taking into account patients in needs of hepatitis B treatment. Actually, for those patients, offering Tenofovir-based HIV PrEP constitutes an opportunity to simultaneously treat their hepatitis B. It requires to integrate WHO recommendations on hepatitis B [19] within PrEP guidelines [20], possibly to simplify hepatitis B care algorithms and to allow hepatitis B care in decentralized sexual health clinics and not only in hospital services. Most efficacy PrEP trials excluded hepatitis B patients. Additional clinical research exploring interactions between HIV PrEP and hepatitis B treatment, in particular the risk of flare if PrEP is stopped, is required.

So far, the focus of HIV programs has mainly been on reaching individuals never tested for HIV, identifying new positives and linking them to HIV care and treatment. Transitioning PrEP from trials to implementation constitutes an opportunity for developing people-centered approaches integrating all sexual and reproductive health services together, including hepatitis B. It is crucial to avoid a silo-based perspective in which services are separated from each other. Moving from HIV care clinics to sexual health clinics would allow to globally improve the health of key populations and their partners, beyond HIV outcomes alone. To ensure the success of new prevention programs, we have to take the next step forward. Beyond biomedical innovations, innovations in terms of intervention implementation, delivery models and public health policies are urgently required [21], in particular in Western and Central Africa [22]. Scaling-up PrEP is a key moment. We should not miss out on this opportunity.

Acknowledgements

The PrEP-CI ANRS 12361 was funded by the Bill and Melinda Gates Foundation and the French National Agency for AIDS and Viral Hepatitis Research (ANRS).

Author contributions: J.L. and V.B. wrote the article. All authors contributed to the interpretation, reviewed the article and approved the final version of the article.

Conflicts of interest

There are no conflicts of interest.
Double-stranded DNA of John Cunningham virus (JCV) contains the early genes region, the late genes region, and the noncoding regulatory region. The large T antigen (LT-Ag), small T antigen, and T proteins encoded by the first region play a critical role in the transformation, genetic regulation, and replication of the virus. The late genes region produces the capsid proteins VP1, VP2, and VP3 in addition to the accessory Agno protein [1,2].